Immune checkpoint inhibitor use in antisynthetase syndrome.

Abstract

We report on the unique case of a patient with antisynthetase syndrome and metastatic non-small cell lung cancer undergoing therapy with the PD-1 checkpoint inhibitor, nivolumab. Despite adequate autoimmune disease control over a period of 12 months, the patient rapidly experienced a flare of interstitial lung disease following initial nivolumab administration, which ultimately proved fatal. The use of immune checkpoint inhibitors in patients with autoimmune disease is becoming more commonplace, however this is the first reported case of the use of these agents in a patient with antisynthetase syndrome. Additionally, the patient's initial clinical presentation with antisynthetase syndrome and simultaneous primary lung cancer, a rare association of which there are few case reports, makes this case interesting and unusual.

• Authors: David Mackintosh, Mohammed F Islam, Jennifer Ng, Jane Basham
• Journal: Asia-Pacific journal of clinical oncology (Asia Pac J Clin Oncol) Vol. 15 Issue 4 Pg. 266-269 (Aug 2019) ISSN: 1743-7563 [Electronic] Australia
• PMID: 30815986 (Publication Type: Case Reports)
• Copyright: © 2019 John Wiley & Sons Australia, Ltd.

Chemical References

• PDCD1 protein, human
• Programmed Cell Death 1 Receptor

Topics

• Carcinoma, Non-Small-Cell Lung (complications, drug therapy)
• Female
• Humans
• Lung Neoplasms (complications, drug therapy)
• Middle Aged
• Myositis (drug therapy, pathology)
• Programmed Cell Death 1 Receptor (antagonists & inhibitors)